311 related articles for article (PubMed ID: 1370437)
1. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
2. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
[TBL] [Abstract][Full Text] [Related]
5. The over-expression of P-glycoprotein in K-562 and DAUDI cells, is associated with a high susceptibility to NK and LAK cells.
Dupuis ML; Ramoni C; Yassen A; Samoggia P; Tombesi M; Caserta M; Cianfriglia M
J Biol Regul Homeost Agents; 1991; 5(4):137-41. PubMed ID: 1687102
[TBL] [Abstract][Full Text] [Related]
6. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
7. Altered conjugate formation and altered apoptosis of multidrug-resistant human leukemia cell line affects susceptibility to killing by activated natural killer (NK) cells.
Treichel RS; Bunuan M; Hahn N; Wee K
Int J Cancer; 2004 Jan; 108(1):78-85. PubMed ID: 14618619
[TBL] [Abstract][Full Text] [Related]
8. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
9. [Morphological observation on NK/LAK cell-mediated lysis of human oral carcinoma cells].
Zheng YJ; Zhang J; Wang SM; Zhang JR
Di Yi Jun Yi Da Xue Xue Bao; 2004 Apr; 24(4):392-6. PubMed ID: 15090306
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of multidrug-resistant human T-lymphoblastoid CEM cell line to cell-mediated cytolysis.
Ramoni C; Dupuis ML; Cenciarelli C; Ciccolini F; Cianfriglia M
Ann Ist Super Sanita; 1990; 26(3-4):433-9. PubMed ID: 1982604
[TBL] [Abstract][Full Text] [Related]
11. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
12. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani EM; Corneo G; Parmiani G
Ann Oncol; 1992 Feb; 3(2):155-62. PubMed ID: 1606087
[TBL] [Abstract][Full Text] [Related]
13. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
Margolin KA; Wright C; Forman SJ
Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
[TBL] [Abstract][Full Text] [Related]
14. Cytocidal activity of PBL, LAK, and IDEC-C2B8 and expression of HLA class 1, ICAM-1, and CD20 in vincristine-resistant hematologic cell lines.
Hirose M; Hamano S; Tobinai K; Kuroda Y
J Immunother; 1999 May; 22(3):237-44. PubMed ID: 10335483
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
[TBL] [Abstract][Full Text] [Related]
16. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
Burkey BB; Omann GM; Wolf GT
Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
[TBL] [Abstract][Full Text] [Related]
17. Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line.
Yanovich S; Hall RE; Weinert C
Cancer Res; 1986 Sep; 46(9):4511-5. PubMed ID: 2425955
[TBL] [Abstract][Full Text] [Related]
18. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
19. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
Correale P; Procopio A; Celio L; Caraglia M; Genua G; Coppola V; Pepe S; Normanno N; Vecchio I; Palmieri G
Cancer Immunol Immunother; 1992; 34(4):272-8. PubMed ID: 1371427
[TBL] [Abstract][Full Text] [Related]
20. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
Teichmann JV; Ludwig WD; Thiel E
Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
